



positive 

January 2018

Safe Harbor Statement

Information contained in this presentation may contain forward-looking statements, including, but not limited to: PositiveID's ability to complete development and commercialization of FireflyDX; PositiveID's ability to successfully market to the professional healthcare, medical testing, biodetection and specialty vehicle market; and PositiveID's ability to reach its revenue projections. These forward-looking statements are not statements of historical fact and represent only PositiveID's beliefs regarding future performance, which is inherently uncertain. There are a variety of factors, many of which are beyond the control of PositiveID, which affect operations, performance, business strategy and results and could cause actual results and experience to differ materially from the expectations and objectives expressed in any forward-looking statements. Additional information about these and other factors that could affect PositiveID's business is set forth in PositiveID's various filings with the Securities and Exchange Commission, including those set forth in PositiveID's Form 10-K filed on March 31, 2017, and Forms 10-Q filed on November 13, 2017, August 14, 2017, and May 15, 2017, under the caption "Risk Factors." PositiveID undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Detection and Diagnostics

- › Three businesses with innovative, disruptive products positioned to revolutionize biological testing, detection and diagnostics
- › Leading molecular diagnostic technologies using multiplex polymerase chain reaction (PCR) chemistry that are accurate, rapid, easy-to-use, cost-effective, assay agnostic
- › Evolving, growing need for infectious disease and bio-threat detection requires point-of-need testing capabilities
- › Proven technologies with 22 patents/patents pending
- › Synergistic product lines, distribution channels, and customer opportunities
- › Strong partners, experienced management
- › 2016 record revenue of \$5.6 million, an increase of 89% over 2015 revenues
- › Third quarter 2017 revenues increase 38% year-over-year; YTD vehicle bookings up over 100% year-over year; forecast continued 30%+ year-over-year growth in Q4 2017 and Q1 2018
- › Large market opportunity for point-of-need diagnostics with FireflyDX: global molecular diagnostics market estimated at \$45B by 2020; global PCR market estimated at \$13B by 2020; food safety testing projected to reach \$19B by 2018
- › Continued growth of the business organically and through complementary acquisitions

Management Team and Advisors

Executives	
William J. Caragol Chairman and CEO	25 years experience managing technology companies, mainly public companies - Deloitte, Condor Technology Solutions, East Wind Partners, Millivision
Lyle L. Probst President	15 years managerial experience in bio-detection, including time at Lawrence Livermore National Labs and SAIC
Dr. Kimothy Smith CSO, ExcitePCR	Former Senior Advisor for International Biodefense for DHS Office of Health Affairs, and Chief Scientist for OHA, leadership experience at LLNL
Gary O'Hara CTO, Thermomedics	25 years experience in med device innovation/bus dev; invented first commercialized infrared tympanic thermometer
Allison Tomek SVP Corp. Dev.	15 years public company experience with technology and healthcare companies - Anrx Corporation, VeriChip
Board of Advisors	
Dr. Paul Schaudies	CEO/Co-Founder of GenArraytion; internationally recognized biotech/biodefense expert; Incident Commander for 2001 anthrax attack in D.C.
Yuval Rabin	Held senior executive positions at AARP, The Principal Group, Ericsson, Airbus Industries, Nokia; son of late Israeli Prime Minister Yitzhak Rabin
Benedikt von Braunmuhl	20+ years healthcare experience, focused on molecular diagnostics; former head of commercial ops of QIAGEN; chairman of Pathoquest
Michael Campbell	Entrepreneur and executive, with specialty in government and political relations; candidate for Lieutenant Gov of SC
Board of Directors	
Ned L. Siegel	Former U.S. Ambassador to the Commonwealth of the Bahamas, Senior Advisor to the U.S. Mission for the 61 st Session of the UN General Assembly
Michael Krawitz	General Counsel York Risk Services Group; 20 years public company experience with technology companies; juris doctorate from Harvard University
Jeffrey Cobb	COO of IT Resource Solutions.net; 25 years executive management experience with technology companies

High Profile Customers and Partners

- › Federal, state & local governments
- › Large commercial integrators
- › Healthcare products distributors
- › Command & communications agencies
 - Pacific Gas & Electric, City of Los Angeles
- › National & state laboratories
 - Sandia, Lawrence Livermore
- › Cellular providers
 - AT&T, Sprint
- › TV stations & broadcast
 - NBC, CBS, and ABC affiliates
- › International customers



Molecular Diagnostics

ExcitePCR
BCB

- › ExcitePCR formed in May 2017 to provide platform for strategic partnership opportunities to capitalize on FireflyDX technology
- › Developing FireflyDX, innovative, accurate, rapid molecular diagnostic (MDx) solutions to disrupt several growing, multi-billion dollar markets
- › FireflyDX products are portable, all-in-one lab MDx solutions that accurately detect pathogens in 30 minutes using real-time PCR, without additional equipment or additional confirmatory testing
- › FireflyDX-Portable is a rechargeable, bookbag-sized, real-time PCR biothreat detection system targeted for launch in late 2018
- › FireflyDX-Handheld is a truly handheld real-time PCR biothreat detection system, targeted for late 2019/early 2020
- › FireflyDX leverages \$35M of investment from U.S. Department of Homeland Security for the development of the predecessor/foundation technology



FireflyDX Advantages

Current Systems	FireflyDX	Benefits of FireflyDX
Large equipment, lab-based testing	Portable, point-of-need testing	Use in clinical or austere settings
Sample-to-result takes hours or even days	Sample-to-result within 30 minutes	Faster testing time results in faster treatment measures
Separate sample prep/purification	Integrated/automated sample prep/purification	Less steps; less room for error/contamination
Highly trained operators required	Minimal training required	Ease of operation; CLIA waiver
Expensive – systems cost \$25K-75K; cost per test ~ \$200-300+	System cost \$5K; cost per test =/<\$25	Affordability; decreases barrier to entry
Use proprietary assays; may use less accurate detection methods	Uses any commercially available assay and TaqMan PCR (“gold standard” detection)	Sensitive and specific results; broadens user pool; no need to submit assays to FDA for approval
Use reduced sample and PCR volumes to speed up testing	Uses standard lab volumes	Improved accuracy; comparable to lab-based results

Mobile Labs



- › ENG Mobile Systems is a specialty vehicle manufacturer with a 25+year operating history
- › Acquired in December 2015 for \$0.9M; sold 49% of ENG in June 2017 for \$1.5M to a strategic partner
- › ENG is a leader in mobile labs, homeland security, command and communications vehicles, and TV and broadcast vans
- › Average revenue of \$4M per year for the last 10 years, with solid gross margins and a strong pipeline of opportunities
 - 2016 revenues totaled \$5M; nine months 2017 revenues totaled \$3.4M with 30% year-over-year growth in Q3 2017 and projected for Q4 2017 and Q1 2018
- › Fastest growing segment of ENG's business is mobile labs, which includes chemical, biological, nuclear, radiological and explosives testing in the field
- › PositiveID's biodetection expertise (through ExcitePCR) combined with ENG's mobile technology creates turnkey mobile lab systems able to conduct analysis and full biological testing-to-result in the field where it's needed most



Medical Devices



- › Thermomedics markets the FDA-cleared Caregiver® thermometer
- › Caregiver is a clinical-grade, infrared thermometer that measures forehead temperature in adults, children, and infants, without contact
- › Caregiver reduces contamination risk and saves medical facilities the cost of probe covers (up to \$0.10 per temp), storage space, and disposal costs
- › Signed agreements with leading healthcare products distributors
- › Preparing to launch a Bluetooth-enabled version of Caregiver to connect wirelessly to patient monitoring stations in Q1 2018
- › Acquisition of Caregiver brings manufacturing and FDA expertise, strong management team, and revenue with strong gross margins
- › Forecasting sales growth of more than 30% for Q4 2017 and Q1 2018
- › With strategic partners in place and pending, Company is targeting \$1M+ run-rate revenue by second half of 2018 and cash flow positive from operations for Thermomedics
- › Global market for medical thermometers forecast to exceed \$1 billion by 2020 with infrared thermometers experiencing the fastest growth driven in part by concerns over the spread of highly infectious diseases like Ebola



Financial Results

Condensed Income Statement and Balance Sheet

\$ in thousands	Three months ended				
	9/30/2017	6/30/2017	3/31/2017	12/31/2016	9/30/2016
Revenue	\$1,467	\$1,225	\$1,227	\$981	\$1,065
Operating loss	\$ (890)	\$ (897)	\$ (1,833)	\$ (1,100)	\$ (3,404)

Capitalization and Balance Sheet

<i>(Shares and \$ in thousands)</i>	<u>Current</u>	⁽¹⁾	<u>Ownership %</u>	
			<u>Basic</u>	<u>Diluted</u>
Equity				
Common Shares	148,181		100.0%	61.0%
Series II Preferred - Board and Mgmt	94,730			39.0%
Diluted Shares	242,911			100.0%
Convertible Debt	\$ 6,148	⁽²⁾		

\$ in thousands		
	9/30/17	12/31/16
Cash	\$ 25	\$ 40
Total Assets	\$ 2,376	\$ 2,562
Total Current Liabilities	\$ 11,362	\$ 11,407
Stockholders' Deficit	\$ (8,996)	\$ (8,863)

(1) Share counts as of November 6, 2017

(2) Convertible notes with embedded derivatives as of September 30, 2017, per Company's Form 10-Q

Highlights

- › \$50M of government funding and internal R&D invested in our IP platform and products developed results in innovative product lines addressing large government and commercial markets with unmet needs
- › Experienced management team; outstanding scientists with proven track records
- › Strong partners/customers and distribution network
- › ExcitePCR to provide platform for strategic partnership/financing opportunities for FireflyDX
- › Vast FireflyDX market opportunity: global MDx market estimated at \$45B by 2020; global PCR market estimated at \$13B by 2020; food safety testing estimated at \$19B by 2018
- › Targeting FireflyDX-Portable for commercial availability in 2018
- › Acquisitions complement long-term strategy and provide near-term revenue and cash flow across synergistic technology platforms
- › \$5.6M of revenue for 2016, an increase of 89% over 2015; 9 months 2017 revenue of \$3.9M
- › Third quarter 2017 revenues increased 38% year-over-year
- › Projecting 30%+ year-over-year consolidated revenue increases for Q4 2017 and Q1 2018 with strong backlog positioning Company for continued growth for all of 2018